重磅丨领星生物宣布完成A轮融资——专注肿瘤精准治疗,让改善触手可及
2017年11月30日，中国上海——领星生物科技（上海）有限公司宣布完成由晨兴创投、杏泽资本和嘉信控股共同参与的A轮融资，华兴资本担任本次融资的独家财务顾问。2015年成立至今，领星共计获得2500万美元资本注入。
November 30, 2017/Shanghai, China—GenomiCare Biotechnology (Shanghai) Co., Ltd. announces the completion of Series A financing co-launched by Morningside Venture Capital, Apricot Tree Capital and Carebridge Holdings, for which China Renaissance Group provides exclusive financial consulting service. Since its inception in 2015, GenomiCare has got total funding of 25 million dollars.
对于此轮融资，领星创始人、总裁兼首席执行官许强博士表示将主要用于以下几个方面的投入：1）加强领星自身能力的建设，更好地为中国肿瘤患者提供精准检测和精准治疗的全时全程管理；2）加速领星精准医疗业务的全国推广，推进与各大医院的战略合作；3）将最全面基因变异数据与患者病理资料和终身随访结合，打造完整的“基因+临床”精准医疗数据库。
Dr. Xu Qiang, the founder, president and CEO of GenomiCare, says the funds will primarily be used to: 1) strengthen self-capability building of GenomiCare, provide more precise testing and better full-solution management for Chinese tumor patients; 2) step up efforts to promote targeted therapy service nationwide, advance strategic collaboration with hospitals; 3) combine the most comprehensive genetic variation data with patients’ pathological data and lifelong follow-up visits, to create complete “genetic + clinical” precise medical database.
领星生物成立于2015年，总部位于上海张江科技园区，在上海张江药谷和江苏启东分别拥有独立的实验室和医学检验所，并与北京大学生命科学华东产业研究院共建了精准医学实验室。领星管理团队由来自北京大学、美国哈佛大学、美国加州大学、中国科学院、复旦大学等国内外著名高校的资深管理人员组成。自成立以来，领星一直致力于为中国的肿瘤患者和医生提供个性化精准医疗的临床解决方案及面向全球资源的对接服务，截至目前已经为国内近3500名患者提供了精准医疗服务。
Founded in 2015, GenomiCare is headquartered in Zhangjiang Hi-tech Park, Shanghai. It respectively owns an independent lab in Shanghai Zhangjiang Yaogu and a medical lab in Qidong, Jiangsu. Meanwhile, it has co-established precision medical lab with East China Institute of Life Sciences Industry of Peking University. GenomiCare management team consists of veteran management staff from Peking University, Harvard University, University of California, CAS, Fudan University, etc. Since its establishment, GenomiCare has been dedicated to provide personalized and targeted clinical solutions and global resource matching service. So far, GenomiCare has provided precise medical services for nearly 3,500 patients in China.
11月30日下午，领星上海总部举办了隆重的“领星生物A轮融资完成庆祝会暨股东董事员工见面会活动”。
On the afternoon of November 30, a grand “Celebration Ceremony for GenomiCare Biotechnology’s Completion of Series A Financing & Shareholder-Director-Employee Meeting” is held at the headquarters of GenomiCare.
作为国内唯一一家为每个患者个性化定制治疗方案的公司，许强博士表示，在中国，很多患者因为没有在最佳的时间得到治疗，往往要承受巨大的治疗折磨和经济损失，且大多数的治疗方式对于晚期患者来说效果不够理想，领星愿意帮助患者和医生在治疗开始前就了解肿瘤的发生机制，更好地为治疗做准备，在患者确诊时就可以得到准确的、有效的治疗选择，并有针对性地监测并发现耐药复发机理，实现长期的临床获益。
As the only company tailoring treatment solutions for every patient in China, Dr. Xu Qiang says, “Many patients miss the best time to get treated, so they often have to suffer huge torments and economic losses. Furthermore, most treatments are far from effective for advanced patients. GenomiCare aims to help patients and doctors understand tumorigenesis mechanism prior to treatment so that patients can receive proper and effective treatment at the time of diagnosis, and drug resistance recurrence mechanism can be effectively monitored and spotted, which helps to achieve long-term clinical benefits.”
嘉信控股CEO葛丰认为：“领星作为国内精准医疗行业的生力军，始终以肿瘤患者实质临床获益为使命，充分重视中国肿瘤患者和医生的需求。相信未来通过团队的不断努力，领星的综合实力将会有进一步的飞跃，推动中国精准医疗的发展并且让更多中国肿瘤患者得到临床获益。”
Carebridge Holdings CEO, Ge Feng, holds, “GenomiCare plays an active role in precise medical industry in China. It is always committed to bring substantial clinical benefits for tumor patients and stays responsive to the needs of Chinese tumor patients and doctors. I believe, with continuous efforts, GenomiCare will grow stronger to drive precise medical development in China and provide clinical benefits for more Chinese tumor patients.”
晨兴创投董事总经理黄璐女士分享了晨兴对领星的认可：“我们非常认同领星的商业理念和团队执行力，在众多的临床医疗服务公司中，领星公司践行的商业模式切实围绕患者的临床需求，旨在为患者提供有临床价值的精准诊疗服务。我们认为这是医疗服务公司能具备持久竞争力和生命力的基础”
Morningside Venture Capital general manager, Huang Lu, shares her recognition of GenomiCare, “We highly recognize GenomiCare’s business philosophy and its team’s execution. Among all the clinical medical service firms, GenomiCare’s business model focuses essentially on clinical needs and strives to offer patients with precise clinical diagnosis and treatment services, which we believe is fundamental for a medical service company to stay competitive and sustainable in the long run. ”
杏泽资本创始合伙人刘文溢表示：“杏泽是一个完整的创业生态系统，我们希望帮助科学家把他们的研究成果推向市场。领星拥有肿瘤精准医疗领域最杰出的科学家，他们不仅在专业领域有深厚积累，而且具备优秀的创业者素质，这在当今生物医药行业中是罕见的。我们希望通过全方位的支持、服务、视野和资源，协助他们实现创业梦想，解决全球肿瘤患者最迫切的医疗需要。”
The co-founder of Apricot Tree Capital, Crystal Liu, comments, “Apricot Tree is a complete entrepreneurial ecosystem. We wish to help put scientists’ research findings to market. GenomiCare has the most prominent scientists in the field of precise tumor therapy. Apart from impressive professional track record, they also possess qualities of successful entrepreneurs, which is uncommon in today’s biomedical industry. We hope to offer comprehensive support, services, perspectives and resources to help them realize their dream and solve the most pressing medical needs for global tumor patients. ”
华兴资本董事总经理、医疗与生命科技组主管谢屹璟表示："领星集肿瘤精准检测与精准治疗资源对接于一体，致力于为患者带来实质性临床获益。领星拥有经验丰富、国际一流的管理团队和世界顶尖的科学顾问专家委员会，在这样优秀团队的带领下，我们相信领星将成为中国肿瘤精准医疗领航者，华兴资本非常荣幸协助公司成功完成这一轮融资。"
The managing director of China Renaissance Group, Kevin Xie delivers, “GenomiCare connects precision medicine detection and therapy resource, dedicates to provide substantial clinical benefits to patients. It has experienced international management team and the world’s top scientific advisory committee. Led by such an excellent team, we believe that GenomiCare will become the leader of precision medicine in China. It is a great honor for us (China Renaissance Group) to help the Completion of Series A Financing.”
关于嘉信控股
综合医疗服务集团嘉信控股有限公司（Carebridge Holdings）致力于打造资源互通的医教研生态体，旗下拥有领星生物科技（上海）有限公司、上海嘉会国际医院等医疗机构及负责《新英格兰医学杂志》官方认证中文数字媒体《NEJM医学前沿》运营的嘉会医学研究和教育集团有限公司。
About Carebridge Holdings
As a comprehensive medical service group,Carebridge Holdings is devoted to build resource-sharing medicine-teaching-research ecosystem. It owns GenomiCare Biotechnology (Shanghai) Co., Ltd., Shanghai Jiahui International Hospital, Jiahui Medical Research & Education Group Co., Ltd. which is responsible for operating NEJMYiXueQianYan that is authorized as Chinese digital platform of The New England Journal of Medicine.
关于晨兴创投
晨兴创投（Morningside Ventures）隶属于晨兴集团，在全球进行高科技风险投资。自1986年创立以来，晨兴创投致力于帮助处于初创期和成长期的生物技术企业，投资涵盖新药研发、临床诊断、医疗器械、医疗服务及数字健康等诸多领域。晨兴创投拥有一支优秀的投资管理团队，多数成员具备公司运营和创业的经验，对于生命科学的前沿、医疗健康产业及不同区域的创业及投资环境，有着深入的理解。
About Morningside Ventures
Morningside Ventures is Morningside Group’s venture arm founded by the Chan Family of Hong Kong in 1986, focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. Morningside Ventures is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.
关于杏泽资本
杏泽资本成立于2015年，由毛伟雄、刘文溢创立，投资团队由全球20多位富有医疗健康领域投资经验的专业人士组成，其专业背景包括生命科学、医药、金融和法律等。目前旗下管理两支人民币基金，管理资产总额超过15亿元人民币。基金的投资人既包括顶尖的专业投资机构和上市公司，也包括知名家族和个人，他们愿为创业者提供有力支持，共同打造世界级的医药公司。自成立至今，杏泽资本专注于投资医疗健康行业早期和成长期的优秀企业，投资项目涵盖生物制药、生命科技、医疗器械、医疗服务及诊断等领域。
About Apricot Capital
Apricot Capital has been investing globally across the healthcare industry: from biopharmaceuticals to medical devices, digital health, diagnostics, and healthcare services. Our team of over 20 distinguished scientific, medical, investment and other professionals manage over 1.5 billion RMB across public and private company investments worldwide. In 2015, our partners saw an OPPOFindXrtunity to build a different kind of private equity fund – one that could discover, build and launch great companies founded on bold ideas that meet at the intersection of science, strategy, business and medicine – where transformational science meets operational reality - providing the best opportunity to dramatically impact the lives of patients.
关于华兴资本
华兴资本集团是中国领先的服务新经济的金融机构，公司业务包括私募融资、兼并收购、证券承销及发行、证券研究、证券销售与交易、私募股权投资、夹层投资、券商资产管理及其他服务，致力于为中国新经济创业者、投资人提供横跨大陆、香港、美国三地的一站式金融服务。
About China Renaissance Group
China Renaissance Group (“CR Group”) is a leading financial institution that combines private placement advisory, M&A advisory, securities underwriting, research, sales and trading, investment management and other financial services. Providing one-stop financial services across mainland China, Hong Kong and the United States, CR Group operates a competitive and unique international network that connects China’s capital markets with the rest of the world, serving new economy entrepreneurs and investors globally.
关于领星生物
领星生物是由中美生物医学科学家携手资深肿瘤专家共同开创的肿瘤精准医疗服务平台，是一家集精准治疗方案筛选、精准治疗实施、精准治疗监测于一体的国际化公司，致力于为中国的肿瘤患者和医生提供个性化精准医疗的临床解决方案及面向全球资源的对接服务。
About GenomiCare
GenomiCare is a precision cancer medicine service platform co-built by Chinese/American biomedical scientists and senior cancer experts, as an international company, it integrates world-class technologies in fields including precision medicine screening, implementation and monitoring. GenomiCare aims to provide personalized clinical precision medicine solutions and global medical resources to Chinese cancer patients and doctors.
